Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...
Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...
Symptoms to look out for and when to see a doctor - There are roughly 10,000 people a year diagnosed with bladder cancer in ...
The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...
A phase 3 clinical trial has shown that patients were 32 per cent less likely to experience cancer recurrence when treated ...
They hope it will be approved by the Medicines and Healthcare Products Regulatory Agency to become the new standard of care.
A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the ...
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...